1-20 of 290
William G. Wierda, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-141716
Published: 2020
Journal Articles

Ibrutinib Induces Durable Remissions in Treatment-Naïve CLL Patients with 17p Deletion/TP53 Mutations: Five Year Follow-up from a Phase 2 Study

Mariela Sivina, Nitin Jain, MD, Ekaterina Kim, PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Maro Ohanian, DO, Michael Andreeff, MD PhD, Mathew Thomas, Philip A. Thompson, MB, MS, Hagop M. Kantarjian, MD, Michael J. Keating, MBBS, Susan M. O'Brien, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-141014
Published: 2020
Journal Articles

Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

John F. Seymour, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Matthew S. Davids, MD, Anthony Mato, MD, Jeff P Sharman, MD, Aimee Cyr, Cynthia Bartkus, German Pena, MD, Michelle Boyer, Simon Sharmokh, MPH, PharmD, Tanya S Rosenberg, MD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-134938
Published: 2020
Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Hun Ju Lee, MD, Michael Y. Choi, MD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Jacqueline C. Barrientos, MD, Nicole Lamanna, MD, Alec Goldenberg, MD, Iris Isufi, MD, Joseph Tuscano, MD, Suki Subbiah, MD, Jean L. Koff, MD, Lori A. Leslie, MD, Gina G Chung, MD, Elizabeth K Weihe, MD, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Frank J Hsu, MD, Michael Wang, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141917
Published: 2020
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Hypertension, Cardiovascular and Renal Complications Observed in Patients with Chronic Lymphocytic Leukemia Receiving Long-Term Therapy with Ibrutinib

Jade Jones, MD, Binsah Susan George, MD, Christine B Peterson, Thao-Mi Tran Ha, Jan A. Burger, MD PhD, Nitin Jain, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Jean-Bernard Durand, MD, Alessandra Ferrajoli, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-141284
Published: 2020
Journal Articles

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

Koji Sasaki, MD, Elias Jabbour, MD, Ghayas C. Issa, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Jeffrey Skinner, MHA, Maria Khouri, Naveen Pemmaraju, MD, Patrice Nasnas, MD, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-142954
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Hua-Jay J Cherng, MD, Nadya Jammal, PharmD, Shilpa Paul, PharmD, Xuemei Wang, MS, Koji Sasaki, MD, Philip A. Thompson, MB, MS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Nitin Jain, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-135938
Published: 2020
Journal Articles

Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Siba El Elhussein, MD, L. Jeffrey Medeiros, MD, Kirill A. Lyapichev, MD, Stephen K. Gruschkus, PhD MPH, Peng Wei, PhD, Ellen Schlette, MD, Warren Fiskus, BSc,PhD, Rashmi Kanagal-Shamanna, MD, Sanam Loghavi, MD, Hong Yang, MD PhD, Shaoying Li, MD, Jie Xu, MD, Zhenya Tang, MD PhD, Beenu Thakral, MD, Nitin Jain, MD, William G. Wierda, MD PhD, Keyur Patel, MD PhD, Kapil N. Bhalla, MD, Joseph D. Khoury, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-143122
Published: 2020
Journal Articles

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Ghayas C. Issa, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Jeffrey Skinner, MHA, Rita Khouri, Naveen Pemmaraju, MD, Patrice Nasnas, MD, Sara E Dellasala, BS, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-143023
Published: 2020
Journal Articles

Genetic Determinants and Evolutionary History of Richter's Syndrome

Erin Michelle Parry, MD PhD, Romain Guieze, MD, Ignaty Leshchiner, PhD, Daniel Rosebrock, Bria Persaud, Camilla K Lemvigh, MSc, Eugen Tausch, MD, Matthew S. Davids, MD, Johannes Bloehdorn, MD, Christof Schneider, MD, Liudmila Elagina, Aina Zurita Martinez, Amaro Taylor-Weiner, PhD, Nitin Jain, MD, William G. Wierda, MD PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Julien Broséus, Florence Cymbalista, MD PhD, Neil E. Kay, MD, Kenneth J. Livak, PhD, Shuqiang Li, PhD, Teddy Huang, BS, Noelia Purroy, MD PhD, Annabelle J Anandappa, MD, Stacey M. Fernandes, BS, Filippo Utro, PhD, Kahn Rhrissorrakrai, PhD, Chaya Levovitz, MD PhD, Brian P Danysh, PhD, Kara Slowik, Sameer A. Parikh, MD, Jennifer R Brown, MD PhD, Laxmi Parida, PhD, Donna S. Neuberg, ScD, Stephan Stilgenbauer, MD, Gad Getz, PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-139456
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Curtis Lachowiez, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Sanam Loghavi, MD, Sa A Wang, MD, Maria Adeoti, R.N., Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD PhD, Nicholas J. Short, MD, Koji Sasaki, MD, Gautam Borthakur, MD, Ghayas C. Issa, MD, William G. Wierda, MD PhD, Naveen Pemmaraju, MD, Guillermo Montalban Bravo, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Lucia Masarova, MD, Musa Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134300
Published: 2020
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, MD, John M. Pagel, MDPhD, Catherine C. Coombs, MD, Nirav N. Shah, MD, Nicole Lamanna, MD, Ewa Lech-Marańda, MD PhD, Toby A. Eyre, Jennifer A. Woyach, MD, William G. Wierda, MD PhD, Chan Yoon Cheah, MBBS, Lindsey E Roeker, MD, Manish R. Patel, MD, Bita Fakhri, MDMPH, Minal Barve, MD, Constantine S. Tam, MBBS, David John Lewis, MD, James N. Gerson, MD, Alvaro J. Alencar, MD, Justin Taylor, MD, Omar Abdel-Wahab, MD, Paolo Ghia, MD PhD, Stephen J. Schuster, MD, Jessica Chen, MS, Binoj Nair, PhD, Donald Tsai, MD PhD, Nora C. Ku, MD, Matthew S. Davids, MD, Jennifer R Brown, MD PhD, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–37.
https://doi.org/10.1182/blood-2020-134970
Published: 2020
Journal Articles

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, MD PhD, Kathleen A. Dorritie, MD, Javier Munoz, MD, Deborah M. Stephens, DO, Scott R. Solomon, MD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, Jerill Thorpe, BS, Tanya Siddiqi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-140622
Published: 2020
Journal Articles

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-140491
Published: 2020